Genomes and Genes
Summary: Tumors or cancer of the human BREAST.
Articles from Journal RESEARCH
Articles from Journal RESEARCH4
Publications263 found, 100 shown here
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyLisa A Carey
Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
JAMA 295:2492-502. 2006..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
- A gene-expression signature as a predictor of survival in breast cancerMarc J van de Vijver
Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
N Engl J Med 347:1999-2009. 2002..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesRichard M Neve
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
Cancer Cell 10:515-27. 2006..We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations...
- A pathway-based classification of human breast cancerMichael L Gatza
Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 107:6994-9. 2010..We propose that this classification scheme provides a basis for understanding the complex mechanisms of oncogenesis that give rise to these tumors and to identify rational opportunities for combination therapies...
- Molecular portraits of human breast tumoursC M Perou
Department of Genetics, Stanford University School of Medicine, California 94305, USA
Nature 406:747-52. 2000..The tumours could be classified into subtypes distinguished by pervasive differences in their gene expression patterns...
- Prospective identification of tumorigenic breast cancer cellsMuhammad Al-Hajj
Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Proc Natl Acad Sci U S A 100:3983-8. 2003..Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies...
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsT Sørlie
Department of Genetics, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, Norway
Proc Natl Acad Sci U S A 98:10869-74. 2001....
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsChristina Curtis
Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
Nature 486:346-52. 2012..Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome...
- The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1Philip A Gregory
Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
Nat Cell Biol 10:593-601. 2008..Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression...
- MicroRNA gene expression deregulation in human breast cancerMarilena V Iorio
Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
Cancer Res 65:7065-70. 2005..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
- ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcomeChristophe Ginestier
Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
Cell Stem Cell 1:555-67. 2007..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
- Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011A Goldhirsch
International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy
Ann Oncol 22:1736-47. 2011..Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints...
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneD J Slamon
Science 235:177-82. 1987..These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer...
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff
American Society of Clinical Oncology, Alexandria, VA, USA
J Clin Oncol 25:118-45. 2007..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersSohrab P Shah
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
Nature 486:395-9. 2012..Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes...
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerSoonmyung Paik
Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
N Engl J Med 351:2817-26. 2004..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
- Supervised risk predictor of breast cancer based on intrinsic subtypesJoel S Parker
Lineberger Comprehensive Cancer Center, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
J Clin Oncol 27:1160-7. 2009..Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen...
- The consensus coding sequences of human breast and colorectal cancersTobias Sjoblom
Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Science 314:268-74. 2006..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
- Tumour invasion and metastasis initiated by microRNA-10b in breast cancerLi Ma
Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
Nature 449:682-8. 2007....
- Involvement of chemokine receptors in breast cancer metastasisA Muller
Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
Nature 410:50-6. 2001..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
- The landscape of cancer genes and mutational processes in breast cancerPhilip J Stephens
Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
Nature 486:400-4. 2012..Among the 100 tumours, we found driver mutations in at least 40 cancer genes and 73 different combinations of mutated cancer genes. The results highlight the substantial genetic diversity underlying this common disease...
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesBrian D Lehmann
Department of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
J Clin Invest 121:2750-67. 2011..These data may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies...
- An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumorsIttai Ben-Porath
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA
Nat Genet 40:499-507. 2008....
- Gene expression profiling predicts clinical outcome of breast cancerLaura J van 't Veer
Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
Nature 415:530-6. 2002..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJose Baselga
Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
N Engl J Med 366:520-9. 2012..In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity...
- Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and FinlandP Lichtenstein
Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
N Engl J Med 343:78-85. 2000..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
- Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasisJing Yang
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
Cell 117:927-39. 2004..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
- Mesenchymal stem cells within tumour stroma promote breast cancer metastasisAntoine E Karnoub
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
Nature 449:557-63. 2007..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
- Matrix crosslinking forces tumor progression by enhancing integrin signalingKandice R Levental
Department of Bioengineering and Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA 19104, USA
Cell 139:891-906. 2009..These data show how collagen crosslinking can modulate tissue fibrosis and stiffness to force focal adhesions, growth factor signaling and breast malignancy...
- Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
J Natl Cancer Inst 101:736-50. 2009....
- Sequence analysis of mutations and translocations across breast cancer subtypesShantanu Banerji
The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
Nature 486:405-9. 2012..The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor...
- The Ki-67 protein: from the known and the unknownT Scholzen
Division of Molecular Immunology, Research Center Borstel, Germany
J Cell Physiol 182:311-22. 2000..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
- Genes that mediate breast cancer metastasis to lungAndy J Minn
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nature 436:518-24. 2005..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
- Multidrug resistance in cancer: role of ATP-dependent transportersMichael M Gottesman
Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Cancer 2:48-58. 2002..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
- Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancerD J Slamon
Department of Medicine, U C L A School of Medicine 90024
Science 244:707-12. 1989..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerAleix Prat
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
Breast Cancer Res 12:R68. 2010..Here, we comprehensively characterize the recently identified claudin-low tumor subtype...
- Most random gene expression signatures are significantly associated with breast cancer outcomeDavid Venet
IRIDIA CoDE, Universite Libre de Bruxelles, Brussels, Belgium
PLoS Comput Biol 7:e1002240. 2011..The methods we present help to overcome this problem...
- Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 351:781-91. 2004..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
- Endogenous human microRNAs that suppress breast cancer metastasisSohail F Tavazoie
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nature 451:147-52. 2008..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond
Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
J Clin Oncol 28:2784-95. 2010..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon
Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
N Engl J Med 344:783-92. 2001..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJose Baselga
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
N Engl J Med 366:109-19. 2012....
- The genomic landscapes of human breast and colorectal cancersLaura D Wood
Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
Science 318:1108-13. 2007..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
- Association of reactive oxygen species levels and radioresistance in cancer stem cellsMaximilian Diehn
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
Nature 458:780-3. 2009....
- Genome remodelling in a basal-like breast cancer metastasis and xenograftLi Ding
The Genome Center at Washington University, St Louis, Missouri 63108, USA
Nature 464:999-1005. 2010..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
- PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancerJ Li
Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
Science 275:1943-7. 1997..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
- Triple-negative breast cancer: clinical features and patterns of recurrenceRebecca Dent
Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
Clin Cancer Res 13:4429-34. 2007..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
- Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry dataM P Coleman
Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
Lancet 377:127-38. 2011..This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival...
- Triple-negative breast cancerWilliam D Foulkes
Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada
N Engl J Med 363:1938-48. 2010..This review focuses on its origin, molecular and clinical characteristics, and treatment...
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupMitch Dowsett
Department of Biochemistry, Royal Marsden Hospital and Breakthrough Breast Cancer Centre, Fulham Road, London, UK
J Natl Cancer Inst 103:1656-64. 2011..These recommendations are geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice...
- Whole-genome analysis informs breast cancer response to aromatase inhibitionMatthew J Ellis
Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
Nature 486:353-60. 2012..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
- A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1Y Miki
Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
Science 266:66-71. 1994..Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology...
- let-7 regulates self renewal and tumorigenicity of breast cancer cellsFengyan Yu
Department of Breast Surgery, No 2 Affiliated Hospital, Sun Yat Sen University, Guangzhou 510120, People s Republic of China
Cell 131:1109-23. 2007..Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target...
- Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane culturesJayanta Debnath
Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
Methods 30:256-68. 2003....
- High frequency of mutations of the PIK3CA gene in human cancersYardena Samuels
Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
Science 304:554. 2004
- Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapyDavid G DeNardo
Department of Pathology, University of California, San Francisco, USA
Cancer Discov 1:54-67. 2011....
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialJacques E Rossouw
Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
JAMA 288:321-33. 2002..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
- Intrinsic resistance of tumorigenic breast cancer cells to chemotherapyXiaoxian Li
Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
J Natl Cancer Inst 100:672-9. 2008....
- Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysisMohammad H Forouzanfar
Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
Lancet 378:1461-84. 2011..Breast and cervical cancer are important causes of mortality in women aged ≥15 years. We undertook annual age-specific assessments of breast and cervical cancer in 187 countries...
- Genome-wide association study identifies five new breast cancer susceptibility lociClare Turnbull
Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 42:504-7. 2010....
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolutionSohrab P Shah
Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada
Nature 461:809-13. 2009..Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression...
- Genes that mediate breast cancer metastasis to the brainPaula D Bos
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nature 459:1005-9. 2009..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
- Generation of breast cancer stem cells through epithelial-mesenchymal transitionAnne Pierre Morel
Centre Leon Berard, Lyon, France
PLoS ONE 3:e2888. 2008..The acquisition of these stem and tumorigenic characters is driven by EMT induction...
- Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Clin Cancer Res 13:3207-14. 2007..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
- Stromal gene expression predicts clinical outcome in breast cancerGreg Finak
McGill Centre for Bioinformatics, 3775 University Street, McGill University, Quebec H3A 2B4, Canada
Nat Med 14:518-27. 2008..Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression...
- Complex landscapes of somatic rearrangement in human breast cancer genomesPhilip J Stephens
Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
Nature 462:1005-10. 2009..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisChristos Sotiriou
Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
J Natl Cancer Inst 98:262-72. 2006..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsM Clarke
Clinical Trial Service Unit, Oxford, UK
Lancet 366:2087-106. 2005..To examine this relationship, collaborative meta-analyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995...
- Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discoveryJessica Kao
Department of Pathology, Stanford University, Stanford, CA, USA
PLoS ONE 4:e6146. 2009..Here, we studied a collection of breast cancer cell lines to catalog molecular profiles and to assess their relation to breast cancer subtypes...
- Diverse somatic mutation patterns and pathway alterations in human cancersZhengyan Kan
Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
Nature 466:869-73. 2010..Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets...
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesJoseph H Taube
Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
Proc Natl Acad Sci U S A 107:15449-54. 2010..Additionally, the expression level of FOXC1, another EMT inducer, correlates strongly with poor survival of breast cancer patients...
- Circulating microRNAs as novel minimally invasive biomarkers for breast cancerHelen M Heneghan
Department of Surgery, National University of Ireland, Galway, Ireland
Ann Surg 251:499-505. 2010..The objective of this study was to investigate the potential of circulating microRNAs as novel breast cancer biomarkers...
- Differential oestrogen receptor binding is associated with clinical outcome in breast cancerCaryn S Ross-Innes
Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Nature 481:389-93. 2012..By establishing transcription-factor mapping in primary tumour material, we show that there is plasticity in ER-binding capacity, with distinct combinations of cis-regulatory elements linked with the different clinical outcomes...
- Breast cancer statistics, 2011Carol DeSantis
Epidemiologist, Surveillance Research, American Cancer Society, Atlanta, GA 30303, USA
CA Cancer J Clin 61:409-18. 2011..Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population...
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersElgene Lim
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Nat Med 15:907-13. 2009..Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors ...
- Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancerBernard Fisher
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
N Engl J Med 347:1233-41. 2002..In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer...
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009A Goldhirsch
International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Ann Oncol 20:1319-29. 2009..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
- Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progressionDouglas S Micalizzi
Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA
J Mammary Gland Biol Neoplasia 15:117-34. 2010..This review focuses on the parallels between epithelial plasticity/EMT in the mammary gland and other organs during development, and on a selection of developmental EMT regulators that are misexpressed specifically during breast cancer...
- Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerYixin Wang
Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
Lancet 365:671-9. 2005....
- Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
N Engl J Med 365:1273-83. 2011..We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab...
- A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasisScott Valastyan
Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
Cell 137:1032-46. 2009..Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis...
- Repeated observation of breast tumor subtypes in independent gene expression data setsTherese Sorlie
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 100:8418-23. 2003..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
- Downregulation of miRNA-200c links breast cancer stem cells with normal stem cellsYohei Shimono
Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, CA 94304, USA
Cell 138:592-603. 2009..The coordinated downregulation of three microRNA clusters and the similar functional regulation of clonal expansion by miR-200c provide a molecular link that connects BCSCs with normal stem cells...
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerLyndsay Harris
Yale Cancer Center, Yale University, New Haven, CT, USA
J Clin Oncol 25:5287-312. 2007..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
- Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cellsLisa B Frankel
Biotech Research and Innovation Centre, Bioinformatics Centre, University of Copenhagen, DK 2200 N Copenhagen, Denmark
J Biol Chem 283:1026-33. 2008..We furthermore found that the tumor suppressor protein Programmed Cell Death 4 (PDCD4) is regulated by miR-21 and demonstrated that PDCD4 is a functionally important target for miR-21 in breast cancer cells...
- MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1Tyler E Miller
Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
J Biol Chem 283:29897-903. 2008..This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker...
- microRNAs exhibit high frequency genomic alterations in human cancerLin Zhang
Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 103:9136-41. 2006..These findings support the notion that copy number alterations of miRNAs and their regulatory genes are highly prevalent in cancer and may account partly for the frequent miRNA gene deregulation reported in several tumor types...
- miR-21-mediated tumor growthM L Si
Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
Oncogene 26:2799-803. 2007..Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target...
- Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signatureEmmanuelle Charafe-Jauffret
Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
Cancer Res 69:1302-13. 2009....
- A multigenic program mediating breast cancer metastasis to boneYibin Kang
Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer Cell 3:537-49. 2003....
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff
American Society of Clinical Oncology, Alexandria, VA and the College of American Pathologists, Northfield, IL, USA
Arch Pathol Lab Med 131:18-43. 2007..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker...
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesPratyaksha Wirapati
Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
Breast Cancer Res 10:R65. 2008....
- Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerCharles L Vogel
University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
J Clin Oncol 20:719-26. 2002..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
- Metastatic behavior of breast cancer subtypesHagen Kennecke
Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
J Clin Oncol 28:3271-7. 2010..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
- Induction of autophagy and inhibition of tumorigenesis by beclin 1X H Liang
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Nature 402:672-6. 1999..These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies...
- Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumorsJason I Herschkowitz
Lineberger Comprehensive Cancer Center
Genome Biol 8:R76. 2007..To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors...
- Trastuzumab--mechanism of action and use in clinical practiceClifford A Hudis
Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
N Engl J Med 357:39-51. 2007
- The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiationTiffany M Phillips
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1714, USA
J Natl Cancer Inst 98:1777-85. 2006..Cancer-initiating cells can now be prospectively isolated from breast cancer cell lines and tumor samples and propagated as mammospheres in vitro under serum-free conditions...
- A systems biology approach for pathway level analysisSorin Draghici
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48202, USA
Genome Res 17:1537-45. 2007..This analysis method has been implemented as a Web-based tool, Pathway-Express, freely available as part of the Onto-Tools (http://vortex.cs.wayne.edu)...
- Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerKenneth R Hess
Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
J Clin Oncol 24:4236-44. 2006..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
- Roles of NF-kB/Rel in the pathogenesis of breast cancerGail E Sonenshein; Fiscal Year: 2012..Thus, pre-clinical testing of green tea components on breast cancer cells that are resistant to antibody therapy will be performed, and if successful, this approach can readily be translated to the clinic. ..
- Prolactin as a Growth Factor in Breast CancerNira Ben-Jonathan; Fiscal Year: 2013..The long term goal is to establish FDA-approved, long acting dopamine agonists as suppressor or PRL secretion, resulting in increased efficacy of chemotherapeutic agents in breast cancer patients. ..
- Developing miRNA diagnostic methods and identifying tumor regulatory networksThomas Tuschl; Fiscal Year: 2010....
- Role of Stat3 in Breast Cancer TumorigenesisJacqueline F Bromberg; Fiscal Year: 2010....
- Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided TherapyPrakash R Rai; Fiscal Year: 2011..Nanotechnology has made major contributions to BrCa therapy. We propose an innovative nanotechnology-based approach for BrCa prevention and treatment that could significantly impact patient care. ..
- PET TUMOR AND PROLIFERATION IMAGING VIA CATIONIC AMINO ACID TRANSPORTJONATHAN EDWARD MCCONATHY; Fiscal Year: 2013..Completion of the research and training plan would position me to become an independent investigator at the conclusion of the award period. ..
- Exercise, Breast Cancer Prevention, and MechanismsHenry J Thompson; Fiscal Year: 2013..The data obtained has the potential to facilitate the translation of pre-clinical and clinical research to public health guidelines for PA directed to cancer prevention and control. ..
- The Role of Long Non-coding RNAs in EMT and Cancer Stem CellsJason I Herschkowitz; Fiscal Year: 2013....
- Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided TherapyPrakash R Rai; Fiscal Year: 2013..This provides the potential for rapid screening to establish individualized patient-specific molecular targets and forms the basis for designing personalized prevention and treatments. ..
- Characterizing Mitochondrial DNA Susceptibility to Breast, Colorectal, and ProstaIona Cheng; Fiscal Year: 2012..In addition, we will evaluate heterogeneity of effects by disease sub-groups, environmental factors and known genetic risk factors. ..
- PROGESTIN AND GROWTH FACTOR CROSS-TALK IN BREAST CANCERCAROL ANN LANGE; Fiscal Year: 2010..This work will aid our understanding of steroid hormone action, and help to identify and implicate new therapeutic targets for breast cancer prevention and treatment. ..
- Pososome Regulated Monocyte/Macrophage Tissue InfiltrationDianne Cox; Fiscal Year: 2013....
- Alcohol and Breast CancerJia Luo; Fiscal Year: 2012..Understanding the interactions among alcohol, ErbB2 and MUC1 will also provide an important insight into the pathogenesis of some human diseases related to alcohol abuse as well as alcohol's teratogenic effect during development. ..
- Role of an RNA-Binding Protein in Mammary CarcinogenesisJeffrey Ross; Fiscal Year: 2009..By investigating the oncogenic properties of the CRD-BP, the RNAs it affects in vivo, and its interactions with tumor-inducing genetic and environmental factors, we hope to uncover novel tumorigenesis pathways. ..
- Mechanisms of Action and Signaling by Steroid Hormone AntagonistsDouglas V Faller; Fiscal Year: 2013....
- Crosstalk between estrogen receptor and NFkB in target gene regulationJonna Frasor; Fiscal Year: 2013....
- MicroRNA Signature of Tamoxifen Resistance in Breast CancerSarmila Majumder; Fiscal Year: 2010..This study will also help us design future clinical trials based on these molecular predictions. ..
- Protein-DNA Drug Carriers for Tumor TargetingLali K Medina-Kauwe; Fiscal Year: 2012..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
- Role of Splicing Factors in Breast CancerOLGA ANCZUKOW-CAMARDA; Fiscal Year: 2013..This plan will establish the basis for my independent research program, in which I plan to contribute to the development of new cancer therapies based on modulating the expression and activity of splicing factors or their targets. ..
- Systems microscopy analysis of tumor cell motility in microenvironment contextBojana Gligorijevic; Fiscal Year: 2013..Results of this study will lead to better understanding of the interplay among microenvironment components during tumor progression and the results will be used to improve diagnosis and treatment of early metastasis. ..
- Mechanisms of Src activation and its role in latent bone metastasis of breast andXiang H F Zhang; Fiscal Year: 2010..Because of the availability of FDA-approved Src inhibitors, this study will carry significant clinical implications and may suggest novel therapeutic strategies that can be immediately subject to clinical trials. ..
- Near-Infrared Fluorescent Choline Kinase Inhibitors for Cancer Imaging and TherapSEAN ARLAUCKAS; Fiscal Year: 2013..Higher-dose regimens will then be formulated, and tumor growth delay and animal survival measurements compared to MN58b. ..
- Regulation of miRNA in breast cancerCarolyn M Klinge; Fiscal Year: 2013....
- Exploiting synthetic-lethal interactions to target triple-negative breast cancersDai Horiuchi; Fiscal Year: 2013..If successful, the proposed research will not only expand our knowledge on MYC biology but will also provide novel therapeutic concepts to be tested again patients with TN tumors. ..
- Genomewide Determinants Of Prognosis And Treatment Of Early-Onset Breast CancerHabibul Ahsan; Fiscal Year: 2010..We will characterize the biological effects of the genetic factors we identify using various techniques comprehensively characterize breast tumors based on molecular features related to tumor DNA and RNA. ..
- Ron Receptor Tyrosine Kinase Signaling in Breast CancerSusan E Waltz; Fiscal Year: 2013..The focus of this proposal is to define the role of a novel protein, termed Ron, and Ron- dependent signaling pathways as potential new therapeutic targets to combat this disease. ..
- Detection of Tumor DNA in Plasma from Carolina Breast Cancer Study PatientsKATHLEEN CONWAY DORSEY; Fiscal Year: 2013..We expect the results of this work will facilitate development of improved biomarkers for cancer diagnosis, treatment effects, and prognosis and disease recurrence in breast cancer. ..
- Role of Phospho-Progesterone Receptors (PR) in Hormone Refractory Breast CancerCAROL ANN LANGE; Fiscal Year: 2013..Our studies on phospho- PR signaling will provide valuable insight into the coordinated regulation of PR and ER function by pathways that can be easily targeted for therapeutic intervention. ..
- Technology to improve the assessment of tissue-associated protein biomarkersJEFFREY THOMAS MASON; Fiscal Year: 2013..It will also facilitate the detection and prognostic assessment of breast tumors at earlier stages where clinical options are greatest and where treatment outcomes are most likely to be favorable. ..
- Non-genomic actions of estrogen in breast cancerEllis R Levin; Fiscal Year: 2013..The clinical significance is to understand new actions of estrogen and tamoxifen that are important to breast cancer biology, possibly targeting membrane or mitochondrial ER for preventing or treating breast cancer. ..
- Regulation of miRNA expression in breast cancer cellsCAROLYN KLINGE; Fiscal Year: 2009..It is our long term hope that miRNAs may provide novel biomarkers and new insights into the mechanisms by which breast tumors gain TAM/antiestrogen-resistance and become invasive and metastatic. ..
- Prevalence of CD24 epigenetic silencing in breast tumors and ERalpha statusBenny Abraham Kaipparettu; Fiscal Year: 2012..Results from this pilot study will provide important data to plan future larger studies to better understand the role of this silencing in therapeutic resistance and clinical outcome. ..
- FUNCTION OF THE CALCIUM SENSING RECEPTOR IN THE BREASTJohn J Wysolmerski; Fiscal Year: 2013..Aim 3 will examine if stimulation of PTHrP production by the CaR contributes to the development of osteolytic bone metastases in vivo. ..
- Imaging Mitochondrial Redox States In Vivo by Hyperpolarized MRLin Z Li; Fiscal Year: 2013..This project may also establish the mitochondrial redox state as a biomarker for cancer diagnosis and treatment response, and a target for therapy. ..
- The role of tristetraprolin in control of breast cancer progressionJianguo Liu; Fiscal Year: 2013....
- INTEGRIN FUNCTION AND SIGNALING IN CARCINOMA PROGRESSIONArthur M Mercurio; Fiscal Year: 2012..The involvement of SOX9 in basal-like tumors and its relationship to the beta4 signature will also be assessed. ..
- A novel biotherapeutic for triple-negative breast cancer.Randolph C Elble; Fiscal Year: 2010..We determine how it causes tumor cell death. We determine the structural feature responsible and its target on the tumor cell. ..
- Mechanisms of Breast Tumor Cell Growth, Motility, and Antiestrogen ResponseAmy H Bouton; Fiscal Year: 2013..abstract_text> ..
- Immunoregulation and immunotherapy of breast cancerRobert H Vonderheide; Fiscal Year: 2012..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
- Immunotherapy of breast cancer with T cells sensitized by cancer stem-like cellsLi Xin Wang; Fiscal Year: 2013..It is anticipated that these studies would provide leads toward development of T cell immunotherapy of breast cancer. ..
- Mitochondrial Genetic Susceptibility to Breast and Prostate CancersIona Cheng; Fiscal Year: 2013..The ultimate application of these findings may improve the prevention, diagnosis and treatment of cancers of the breast and prostate. ..
- Asthma is a Prognostic Indicator for Pulmonary Metastasis of Breast CancerJAMES JOSEPH LEE; Fiscal Year: 2010..g., enhanced treatment protocols) aggressively targeting the asthma of breast cancer patients with the expectation of increased survival rates among this large subset of breast cancer patients. ..
- Targeting Cathepsin L: A Novel Strategy to Impede Prostate and Breast Cancer MetaDietmar W Siemann; Fiscal Year: 2013....
- Identifying a network of microRNAs and genes that regulate breast tumor metastasiHuiping Liu; Fiscal Year: 2012..This application proposes a 1-year mentored phase (100% effort) and a 3-year independent phase (80% effort) to complete the research and training goals. ..
- Improved Drug Delivery to Tumors Using Novel Tissue Perfusion ApproachesHEIKE ELIZABETH DALDRUP-LINK; Fiscal Year: 2012..abstract_text> ..
- TRANSCRIPTIONAL REGULATION OF BREAST CANCER METASTASISZena Werb; Fiscal Year: 2012..We postulate that GATA-3 maintains the differentiation of breast neoplasms, and its loss plays a causal role in malignant progression: During neoplastic progression, GATA-3 maintains ..
- Role of CITED2 in Breast Cancer Bone MetastasisScott L Kominsky; Fiscal Year: 2013..If successful, these studies will identify a novel mediator of bone metastasis and a new avenue for its prevention and treatment. ..
- Role of PALB2 in the DNA damage response and breast cancer suppressionBing Xia; Fiscal Year: 2013..g. double strand breaks, interstrand crosslinks, etc. Finally, in the longer term the mouse models generated and characterized here may prove useful for pre-clinical testing of cancer drugs. ..
- Regulation of Breast Cancer Growth by MLK-3AJAY NMN RANA; Fiscal Year: 2013..Further, our results will point to the possibility of utilizing MLK inhibitor(s) as a novel therapeutic intervention for breast cancer therapy. ..
- The optimization of compounds that selectively inhibit protein synthesis for theCATHY A SWINDLEHURST; Fiscal Year: 2013....
- Cell Death Regulation in Lumen Formation and OncogenesisJOAN SIEFERT BRUGGE; Fiscal Year: 2012....
- Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ERChristopher Benz; Fiscal Year: 2013....
- Role of CCN6 (WISP3) in the progression and metastasis of breast cancerCelina G Kleer; Fiscal Year: 2012..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..
- Targeting the COX-2 Pathway to Reduce Breast Cancer MortalityAmy M Fulton; Fiscal Year: 2012..We will examine these relationships further in order to identify how to restore the balance between protective and anti-protective EP receptor function to reduce mortality from metastatic breast cancer. ..
- Breast cancer prevention with NexrutineSUSAN PATRICIA LANZA-JACOBYY; Fiscal Year: 2012..We also plan to determine mechanisms by which Nexrutine is inducing autophagy by interrogating the role of ERK and Akt/mTOR signaling and reactive oxygen species (ROS) in mediating these effects. ..
- Mechanisms of ATF3-induced mammary tumorigenesisMichael C MacLeod; Fiscal Year: 2011..abstract_text> ..
- MCJ function in mouse mammary tumor propertiesMercedes Rincon; Fiscal Year: 2009..Considering the strong need for chemotherapy response biomarkers in cancer, this project is highly relevant for human health. ..
- Environmental Epigenetics and Stem/Progenitor Cell InjuryTim H M Huang; Fiscal Year: 2010..These loci are future biomarkers for early breast cancer detection and are putative biosensors to environmental estrogens. ..
- Second line breast cancer therapy through a novel PhytoantiestrogenSYREETA LATATIA TILGHMAN; Fiscal Year: 2013....
- BP1 and Nuclear Hormone Signaling in Breast CancerJOSEPH PINZONE; Fiscal Year: 2009..Schwartz, Fontana, and Ascensao will provide overarching scientific and career guidance and independent ongoing peer review. Finally, Dr. Schaffner will mentor my training in the responsible conduct of research. ..
- Characterization of a GPCR-blocking antibody for the treatment of breast cancer.GARRET GUENTHER; Fiscal Year: 2011..Completion of the proposed project will determine if this new drug is likely to be effective in treating breast tumors. ..
- Epidemiology of Breast Cancer Subtypes in African American Women: a ConsortiumJulie R Palmer; Fiscal Year: 2013..By pooling our data, specimens, and importantly, expertise to investigate these synergist hypotheses, we will elucidate much of the etiology of aggressive, early onset breast cancers in AA women. ..
- Effects of herbs on transcription and cell proliferationDale Leitman; Fiscal Year: 2003..This information can also provide a scientific basis to prioritize herbs for clinical trials evaluation for their ability to prevent and treat breast cancer. ..
- Molecular Epidemiology of Secondary Lung CancerPeter Shields; Fiscal Year: 2007..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description, ..
- MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURESWilliam Baird; Fiscal Year: 2005..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
- RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPYJohn Katzenellenbogen; Fiscal Year: 2006..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
- HETEROGENEITY OF ESTROGEN RECEPTOR STRUCTURE AND ACTIONBeth Schachter; Fiscal Year: 1993....
- BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP & TGFBTheresa Guise; Fiscal Year: 2000..Combinations of bisphosphonates with factor-specific therapy will be studied for synergistic effects. ..
- ORGANOCHLORINE COMPOUNDS AND RISK OF BREAST CANCERTongzhang Zheng; Fiscal Year: 1993..Statistical analyses will be performed using standard multivariable techniques to address the study hypotheses and to control for confounding...
- Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosisSusan McCann; Fiscal Year: 2009....
- Molecular Epidemiology of Smoking & Breast CancerKATHLEEN CONWAY DORSEY; Fiscal Year: 2005..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
- Interactions Between Dietary Soy Components & TamoxifenJin Rong Zhou; Fiscal Year: 2003....
- Dietary lignan effects on hormone, growth, and signaling factors in breast tumorsSusan McCann; Fiscal Year: 2009..The results of this study may provide us with important information that can be useful in understanding the effect of diet on development of different breast cancer sub-types. ..
- Coexpression of EGFRvlll/ErbB2 in Human Breast CancerCareen Tang; Fiscal Year: 2005..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
- Int5/Aromatase Effect of Breast Estrogen in NeoplasiaRAJESHWAR TEKMAL; Fiscal Year: 2005..abstract_text> ..
- ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPYGiuseppe Pizzorno; Fiscal Year: 2004..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
- Breast CT scanner for earlier cancer detectionJohn Boone; Fiscal Year: 2002..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
- Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast CancerRaghuraman Kannan; Fiscal Year: 2009..This has the potential to improve the early detection and diagnosis of breast cancer. ..